List of Excipients in Branded Drug TODAY VAGINAL CONTRACEPTIVE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayer Laboratories Inc	TODAY VAGINAL CONTRACEPTIVE	nonoxynol-9	44376-100	BENZOIC ACID
Mayer Laboratories Inc	TODAY VAGINAL CONTRACEPTIVE	nonoxynol-9	44376-100	CITRIC ACID MONOHYDRATE
Mayer Laboratories Inc	TODAY VAGINAL CONTRACEPTIVE	nonoxynol-9	44376-100	MONOSODIUM CITRATE
Mayer Laboratories Inc	TODAY VAGINAL CONTRACEPTIVE	nonoxynol-9	44376-100	SODIUM METABISULFITE
Mayer Laboratories Inc	TODAY VAGINAL CONTRACEPTIVE	nonoxynol-9	44376-100	SORBIC ACID

TODAY Vaginal Contraceptive Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

TODAY Vaginal Contraceptive is a single-use vaginal sponge containing 1 gram of nonoxynol-9 in a polyurethane foam matrix. Its commercial value depends less on active-ingredient exclusivity than on foam engineering, nonoxynol-9 release control, usability, manufacturing consistency, regulatory positioning, and brand distribution. The strongest opportunities are improved comfort, reduced leakage, better shelf stability, discreet packaging, and next-generation nonhormonal delivery platforms.

What is TODAY Vaginal Contraceptive?

TODAY Vaginal Contraceptive is a vaginal contraceptive sponge containing nonoxynol-9, a surfactant spermicide. The polyurethane sponge absorbs vaginal fluids, conforms to the vaginal canal, and releases nonoxynol-9 locally. The product is intended for single use and is removed after intercourse within the labeled use period.[1]

Attribute	Product profile
Product	TODAY Vaginal Contraceptive Sponge
Active ingredient	Nonoxynol-9
Dose	1 gram per sponge
Dosage form	Vaginal sponge
Matrix	Polyurethane foam
Route	Intravaginal
Use	Single-use, on-demand contraception
Hormonal status	Nonhormonal
Product category	Vaginal contraceptive drug product
Principal commercial differentiator	Drug-loaded polymeric delivery system

The sponge provides both a physical barrier and a chemical contraceptive effect. Nonoxynol-9 disrupts sperm-cell membranes, while the sponge blocks access to the cervix.

What excipients are used in TODAY Vaginal Contraceptive?

The publicly available product labeling identifies polyurethane foam as the inactive structural ingredient.[1] The formulation strategy is therefore relatively simple compared with creams, gels, tablets, or rings. The foam is not an inert packaging component. It controls product geometry, fluid uptake, drug distribution, release, handling, and removal.

Polyurethane foam

Polyurethane is the core excipient and delivery matrix. Its commercial performance depends on:

• Open-cell structure and pore-size distribution
• Foam density
• Compression and recovery behavior
• Fluid absorption capacity
• Mechanical strength when wet
• Nonoxynol-9 loading uniformity
• Drug migration during storage
• Residual monomers, catalysts, solvents, and processing chemicals
• Extractables and leachables
• Compatibility with the primary package

A foam with excessive absorption may sequester nonoxynol-9 and reduce release into vaginal fluid. A foam with insufficient absorption may leak, deform, or provide poor physical retention. The target is controlled fluid uptake with rapid and reproducible drug availability.

Nonoxynol-9 compatibility

Nonoxynol-9 is a nonionic surfactant. Its interaction with polyurethane can affect:

• Foam swelling
• Surface wetting
• Drug distribution
• Release kinetics
• Mechanical integrity
• Storage stability

The formulation should be assessed under simulated vaginal-fluid conditions and across clinically relevant temperature and humidity ranges. Surfactant migration into the package can create dose-uniformity problems and may cause seal or material-compatibility issues.

Potential secondary excipients

A redesigned product could use additional materials, but each addition would increase regulatory and technical complexity. Potential candidates include:

Excipient class	Commercial purpose	Main development risk
Humectants	Improve wetting and handling	Alter drug release and microbial stability
pH modifiers	Support spermicide activity or tolerability	Vaginal irritation and microbiome effects
Mucoadhesive polymers	Improve retention	Difficult removal and residue
Lubricants	Improve insertion and comfort	Drug migration and package compatibility
Antioxidants	Protect susceptible components	New safety and extractables assessment
Plasticizers	Modify softness and flexibility	Leachables and mechanical instability
Biodegradable polymers	Enable new delivery systems	New regulatory and manufacturing pathway

For TODAY-type products, a minimal-excipient strategy is commercially attractive. Every new excipient must justify its effect on safety, performance, and user experience.

How should the excipient strategy be optimized?

The highest-value formulation work should focus on the polyurethane matrix rather than adding multiple inactive ingredients.

Optimize foam density and pore architecture

Foam engineering can improve dose release and physical performance without changing the active ingredient. Key development variables include:

1. Foam density and porosity
2. Pore interconnectivity
3. Compression force and recovery time
4. Wet tensile strength
5. Fluid uptake rate
6. Drug-loading uniformity
7. Release profile after insertion

A narrower manufacturing specification for pore size and density could reduce batch variability. That improvement may support stronger regulatory comparability data and reduce complaints involving inconsistent insertion, leakage, or removal.

Improve comfort and insertion

User experience is a major commercial constraint. The sponge must be soft enough for insertion but sufficiently resilient to maintain position. Product improvements could include:

• A smoother insertion surface
• Lower insertion force
• A redesigned retrieval feature
• Reduced edge friction
• Better anatomical conformity
• A lower-profile package
• Lubrication integrated into the product or package

A comfort-focused product could target users who reject condoms, dislike hormonal contraception, or need a nonprescription contraceptive option used only when needed.

Control nonoxynol-9 release

The product should provide rapid availability after exposure to vaginal fluid while maintaining adequate local concentration over the labeled use period. Development programs should characterize:

• Initial burst release
• Total released dose
• Release after repeated intercourse
• Drug remaining in the sponge after removal
• Release under different vaginal-fluid volumes
• Release after aging
• Interbatch variability

A controlled-release design could create a commercially differentiated product. It would also require clinical or bridging evidence showing that altered release does not reduce contraceptive effectiveness or increase irritation.

Reduce irritation potential

Nonoxynol-9 has been associated with vaginal and cervical irritation, particularly with frequent use. The Centers for Disease Control and Prevention advises against using nonoxynol-9 for HIV prevention because repeated exposure can increase genital irritation and may increase HIV acquisition risk in high-risk settings.[2]

A new formulation should therefore evaluate:

• Local tissue irritation
• Epithelial integrity
• Inflammatory markers
• Vaginal microbiome effects
• Use with repeated intercourse
• Use during menstruation
• Interaction with lubricants and other vaginal products

A lower-irritancy formulation could have a stronger commercial position than a simple low-cost copy.

What FDA regulatory status applies to TODAY Vaginal Contraceptive?

TODAY Vaginal Contraceptive is an FDA-regulated vaginal contraceptive drug product containing nonoxynol-9. FDA regulation of vaginal contraceptive products addresses active-ingredient safety and effectiveness, labeling, dosage form, and manufacturing controls.[3]

The product is not a biologic, so biosimilar competition does not apply. It is also not a conventional implantable device. Its drug-loaded foam structure creates drug-device combination-product issues for any materially redesigned version.

Regulatory routes for improved products

Product change	Likely regulatory concern
Same foam and same dose	Manufacturing change, stability, comparability
New foam density or pore structure	Drug-release and performance comparability
New excipient	Safety, irritation, toxicology, CMC
New dose of nonoxynol-9	Effectiveness and local tolerability
Extended-use claim	New clinical and microbiological evidence
New delivery mechanism	Potential 505(b)(2) or combination-product pathway
New active contraceptive	Full efficacy and safety development program

A product that retains the same active ingredient but changes the matrix, use period, or release profile may require more than a routine manufacturing supplement. The regulatory burden will depend on whether the change affects clinical performance.

What is the Orange Book status of TODAY Vaginal Contraceptive?

TODAY Vaginal Contraceptive does not present the same Orange Book commercial profile as a currently marketed prescription drug with a large patent estate. Its principal competition is likely to arise from:

• OTC nonoxynol-9 products
• Condoms
• Hormonal contraceptives
• Copper intrauterine devices
• Prescription vaginal contraceptive gels
• Emerging nonhormonal products
• Private-label or retailer-distributed alternatives

Paragraph IV litigation is not the principal near-term risk for this product category. A competitor would more likely pursue an OTC drug route, an abbreviated or comparative pathway where available, or a new drug application for a materially different product.

The brand owner’s defensibility is therefore more likely to come from manufacturing know-how, tooling, validated foam specifications, regulatory history, trademarks, distribution, and consumer recognition than from broad, enforceable compound patents.

What patents protect TODAY Vaginal Contraceptive?

The product’s potential patent protection is concentrated in the delivery system rather than in nonoxynol-9 itself. Nonoxynol-9 is an old active ingredient with limited practical exclusivity value. Relevant patent categories include:

• Drug-loaded polyurethane sponge compositions
• Foam pore architecture
• Nonoxynol-9 loading processes
• Controlled-release vaginal matrices
• Sponge shape and retrieval structures
• Packaging that preserves dose uniformity
• Manufacturing methods
• Combination use with lubricants or other contraceptive agents

Patent protection is only commercially meaningful if claims remain unexpired, cover the marketed configuration, and are enforceable in the target jurisdiction. For a legacy product, expired composition or delivery patents may still provide technical guidance but do not block competition.

Patent strength assessment

IP category	Likely strength for a legacy sponge	Commercial relevance
Nonoxynol-9 composition claims	Low	Active ingredient is old
Generic polyurethane sponge claims	Low to moderate	Easy design-around risk
Specific foam architecture	Moderate	Can protect performance-critical parameters
Manufacturing process	Moderate	Can create know-how barriers
Packaging and stability	Low to moderate	Useful if tied to dose preservation
Brand and trade dress	Moderate	Important in OTC retail
New controlled-release platform	Potentially high	Requires meaningful technical differentiation

Patent searches should focus on assignee continuity, terminal disclaimers, maintenance-fee status, continuations, foreign counterparts, and claim scope rather than relying on product-name searches alone.

What commercial opportunities exist for excipient innovation?

1. Premium nonhormonal sponge

A modernized sponge could compete as a premium OTC contraceptive with improved comfort, discreet packaging, and a more reliable retrieval system. The product could target users seeking control over the timing of contraception without daily dosing or hormonal exposure.

2. Lower-irritancy spermicide platform

A reformulated nonoxynol-9 product with reduced local irritation could address the principal limitation of frequent spermicide use. This opportunity requires strong mucosal safety data and careful claims strategy. The product should not imply protection against sexually transmitted infections.

3. Combination contraceptive sponge

A sponge could potentially combine nonoxynol-9 with another contraceptive active or a pH-modifying system. Such a product would face higher development costs, more complex toxicology, and a greater risk of drug-drug or excipient interactions.

4. Extended-use product

A product designed for longer retention or repeated intercourse could improve convenience. The key barriers are microbial growth, local irritation, dose depletion, mechanical integrity, and user-removal behavior. An extended-use claim would need evidence beyond the current labeled use pattern.

5. Private-label manufacturing

A validated polyurethane sponge platform could support retailer, telehealth, and family-planning channels. The opportunity is strongest if the manufacturer controls:

• Foam production or exclusive sourcing
• Nonoxynol-9 loading
• Automated cutting and shaping
• Sterilization or bioburden controls
• Packaging
• Stability testing
• FDA-quality documentation

Private-label competition could increase volume but compress margins and weaken brand differentiation.

6. International expansion

The product may have commercial relevance in markets where OTC, on-demand, nonhormonal contraception is underdeveloped. Geographic expansion requires country-specific review of:

• Nonoxynol-9 status
• Vaginal drug classification
• Device-drug combination rules
• Local contraceptive labeling
• Language and human-factors requirements
• Import and manufacturing controls
• Patent and trademark clearance

A polyurethane sponge may be easier to commercialize than a new molecular contraceptive, but regulatory classification differs by jurisdiction.

How does TODAY compare with competing contraceptives?

Product type	Hormonal	Prescription	On-demand	Principal advantage	Principal limitation
TODAY sponge	No	Generally no	Yes	Local, reusable only for labeled period, user-controlled	Irritation, insertion and removal
Condom	No	No	Yes	STI protection when used correctly	Breakage, fit, adherence
Vaginal contraceptive gel	No	Varies	Yes	No insertion device retained	Repeated application
Oral contraceptive	Yes	Usually yes	No	High effectiveness with adherence	Daily use and systemic exposure
Vaginal ring	Yes	Usually yes	No	Monthly or extended dosing	Hormonal exposure
IUD	Copper or hormonal	Yes	No	Long duration and high effectiveness	Insertion procedure
Diaphragm	No	Varies	Yes	User-controlled barrier	Fitting and spermicide use

The TODAY product is positioned between condoms and prescription long-acting methods. It offers privacy and user control but does not match long-acting methods in typical-use effectiveness.

What generic entry risks exist for TODAY?

Generic or private-label entry risk is moderate if a competitor can reproduce the same functional profile without infringing valid claims. The principal barriers are:

• Consistent foam manufacturing
• Nonoxynol-9 dose uniformity
• Product-performance testing
• Package stability
• Consumer trust
• Retail distribution
• Regulatory documentation
• Availability of suitable polyurethane foam suppliers

The risk increases if the product has no active formulation or process patents and if its regulatory pathway permits close copies. The risk decreases if the brand owner controls specialized tooling, proprietary foam specifications, manufacturing know-how, or clinically supported performance claims.

What litigation and settlement issues affect the product?

The main legal risks are likely to involve product liability, labeling, advertising claims, manufacturing defects, and trademark rights rather than biosimilar or conventional Paragraph IV litigation. Potential disputes could concern:

• Claims about contraceptive effectiveness
• Statements regarding STI protection
• Irritation or adverse-event warnings
• Manufacturing consistency
• Product contamination
• Infringement of sponge or packaging patents
• Private-label copying
• Trademark and trade-dress similarity

Settlement agreements involving generic entry cannot be assessed as a central market factor without a confirmed active patent dispute. For a legacy OTC contraceptive, commercial settlements are more likely to relate to supply, distribution, trademark, or manufacturing arrangements.

What is the revenue opportunity?

Revenue depends on retail price, repeat use, distribution, and market education. The most attractive commercial model is a differentiated OTC product sold through pharmacies, reproductive-health platforms, online channels, and family-planning providers.

A premium strategy could monetize:

• Improved comfort
• Lower-irritancy positioning
• Better packaging
• Discreet subscription replenishment
• Multi-unit packs
• Private-label supply
• International licensing
• Co-branding with sexual-health companies

The product is unlikely to support pharmaceutical-style pricing. Its value lies in recurring consumer purchases, low manufacturing cost after scale-up, and access to a nonhormonal contraception segment.

Key Takeaways

• TODAY Vaginal Contraceptive uses polyurethane foam as its principal excipient and delivery matrix.
• Nonoxynol-9 is an old active ingredient, so exclusivity is more likely to depend on formulation, process, brand, and distribution.
• Foam density, pore structure, wet strength, dose uniformity, and release control are the main technical levers.
• The strongest product opportunity is a more comfortable, lower-irritancy, better-packaged nonhormonal sponge.
• Extended-use and combination products would carry materially higher regulatory and clinical risk.
• Biosimilar competition is irrelevant because the product is not a biologic.
• Paragraph IV litigation is not the dominant risk profile for this legacy OTC vaginal contraceptive.
• Manufacturing know-how and validated polyurethane specifications may provide greater practical protection than expired or narrow patents.
• Private-label manufacturing and international distribution are credible commercial opportunities.
• Any new excipient or altered release profile could trigger substantial comparability, toxicology, and combination-product review.

FAQs About TODAY Vaginal Contraceptive Excipient and Commercial Strategy

Can a different foam replace polyurethane in TODAY Vaginal Contraceptive?

Yes, but replacement would require comparative evaluation of drug loading, release, mechanical integrity, irritation, extractables, stability, and contraceptive performance. A different polymer could create a materially new product rather than a simple manufacturing change.

Can TODAY Vaginal Contraceptive be reformulated without nonoxynol-9?

Yes, but it would become a new contraceptive product concept. Removing nonoxynol-9 would eliminate the existing spermicide mechanism and require evidence for the replacement mechanism.

Is a mucoadhesive excipient commercially attractive for a vaginal sponge?

It may improve retention, but it could complicate removal, increase residue, alter drug release, and raise local tolerability concerns. Mucoadhesion is more attractive for a redesigned delivery system than for a direct TODAY substitute.

Could a new TODAY-type sponge qualify for patent protection?

Potentially. Patentable subject matter could include a specific foam architecture, release profile, manufacturing process, combination formulation, or use method. Generic claims covering a nonoxynol-9 sponge would face substantial validity and prior-art risk.

Does nonoxynol-9 provide protection against sexually transmitted infections?

No. Nonoxynol-9 should not be marketed as an STI-prevention product. Condom-based strategies remain the relevant barrier approach for reducing STI transmission risk.[2]

References

1. National Library of Medicine. (n.d.). DailyMed: TODAY vaginal contraceptive sponge, nonoxynol-9 insert. U.S. National Library of Medicine.

2. Centers for Disease Control and Prevention. (2021). U.S. selected practice recommendations for contraceptive use, 2016: Adapted from the World Health Organization selected practice recommendations for contraceptive use, third edition. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Vaginal contraceptive drug products; over-the-counter human use. Code of Federal Regulations, 21 C.F.R. Part 310.